Choriogonadotropin alfa (human)

Choriogonadotropin alfa (Chorionic gonadotropin) (human) is a glycoprotein that binds to Follicle stimulating hormone receptor FSHR and results in ovulation. Choriogonadotropin alfa (human) is an analogue of Luteinizing Hormone (LH), and interacts with luteinizing hormone/choriogonadotropin (LHCGR). Choriogonadotropin alfa (human) can be used in the research of infertility, ovulation, breast cancer, neurological disesase^[1][2][3][4]. IC50 & Target: FSHR, LHCGR^[3]. In Vitro: Choriogonadotropin alfa (human) (20 μM, 24 h) increases late apoptosis and cell death ratio in MCF-7 cells^[1].
Choriogonadotropin alfa (human) (20 μM, 24 h) increases G2/M arrest in MCF-7 cells^[1].
Choriogonadotropin alfa (human) (10 IU/mL, 24 h) increases IL-1β and LIF expression levels in human peripheral blood mononuclear cells (PBMC)^[2].
Choriogonadotropin alfa (human) (10 IU/mL, 24 h) activates PBMC in JAR cell invasion by upregulating MMP-2, MMP-9, and VEGF expressions and downregulating TIMP-1 and TIMP-2 expressions^[2].
Choriogonadotropin alfa (human) (1 IU/mL, 24 h) increases mRNA level in EGF pathway, steroidogenesis genes, STAR protein production, and progesterone secretion in mural granulosa cells (MGCs)^[3]. In Vivo: Choriogonadotropin alfa (human) (intraperitoneal injection, 200 IU/200 μL, daily for three days) increases the number of hCG receptor-ir (hCG receptor-immunoreactive) neurons in the cerebellum and prefrontal cortex of rats models of Alzheimer's disease^[3].
Choriogonadotropin alfa (human) (intraperitoneal injection, 5-10 IU in 100 μL) increases the mean number of embryos, but decreases the proportion of morphologically normal embryosl in female C57Bl/6J/Bom mice^[4].